(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.79%.
Imunon's earnings in 2025 is -$17,793,212.On average, 3 Wall Street analysts forecast IMNN's earnings for 2025 to be -$12,622,078, with the lowest IMNN earnings forecast at -$14,620,732, and the highest IMNN earnings forecast at -$10,819,342. On average, 3 Wall Street analysts forecast IMNN's earnings for 2026 to be -$11,257,964, with the lowest IMNN earnings forecast at -$20,469,025, and the highest IMNN earnings forecast at -$5,263,464.
In 2027, IMNN is forecast to generate -$5,775,189 in earnings, with the lowest earnings forecast at -$7,017,951 and the highest earnings forecast at -$4,532,427.